Search results
Showing 616 to 630 of 1835 results for carers
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]
Awaiting development Reference number: GID-TA11417 Expected publication date: TBC
Awaiting development Reference number: GID-TA11549 Expected publication date: TBC
Awaiting development Reference number: GID-TA11507 Expected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]
Awaiting development Reference number: GID-TA11383 Expected publication date: TBC
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]
Awaiting development Reference number: GID-TA11881 Expected publication date: TBC
Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]
Awaiting development Reference number: GID-TA11883 Expected publication date: TBC
Awaiting development Reference number: GID-TA11706 Expected publication date: TBC
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
Awaiting development Reference number: GID-TA11641 Expected publication date: TBC
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]
Awaiting development Reference number: GID-TA11886 Expected publication date: TBC
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]
Awaiting development Reference number: GID-TA11721 Expected publication date: TBC
children and young people with IgE-mediated food allergy and their parents or carers want to know during the process of diagnosis and...
Awaiting development Reference number: GID-TA11534 Expected publication date: TBC
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Initial education in adrenaline auto-injector use
- Quality statement 2: Referral to specialist allergy services after emergency treatment
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4: Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.